Otonomy

Otonomy Dividend

Delisted

Dividend of Otonomy (OTIC) as of Nov 10, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Otonomy 2026 pay?

According to the latest status from November 2026, Otonomy paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Otonomy price of 0.00 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Otonomy Dividends

Historical Otonomy Dividends
PaydateDividend
0.11USD

The Otonomy Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2021
0.00 USD
Jan 1, 2022 (e)
0.00 USD
Jan 1, 2023 (e)
0.00 USD
Jan 1, 2024 (e)
0.00 USD
Jan 1, 2025 (e)
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
The Otonomy Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the Otonomy Dividend Safe?

Otonomy has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Otonomy's Dividend Distributions

Otonomy’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Otonomy's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Otonomy's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Otonomy’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Otonomy stock

Otonomy is assigned to the 'Health' sector.

The dividends of Otonomy are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Otonomy